In February 2022, Russian figure-skating prodigy Kamila Valieva became the center of one of the most consequential Olympic doping disputes in years after a sample collected before the Beijing Games tested positive for trimetazidine, a banned heart medication. The result arrived only after Valieva had helped the Russian Olympic Committee win the team event, creating an extraordinary crisis: the 15-year-old was provisionally suspended, then allowed to continue competing while appeals were heard. Her status as a protected minor and the delayed laboratory reporting became central to the legal battle, while the controversy cast doubt over the team-event medals and the integrity of the Olympic figure-skating competition.
Denis Oswald, a senior International Olympic Committee official and head of its Disciplinary Commission, was retained to represent Valieva. He argued that the positive result could have been caused by contamination from medication taken by Valieva’s grandfather, a defense that attracted intense international scrutiny but was never established as a definitive explanation. Valieva competed under immense pressure, fell repeatedly in the individual event, and finished fourth. The Court of Arbitration for Sport later imposed a four-year ban, ultimately disqualifying her results from December 25, 2021 onward and forcing the reworking of the Beijing team-event standings. The case became another emblem of the continuing conflict between Olympic anti-doping rules, the protection of minors, and the powerful legal machinery surrounding Russian athletes.
Follow the sources
Status and citations are supplied by the archive. AI concept art is an interpretation, not historical evidence.